Lyell Immunopharma, Inc. (Nasdaq: LYEL) is set to present initial clinical data from its Phase 1-2 study of IMPT-314 in patients with large B-cell lymphoma at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, CA, December 7 – 10, 2024. IMPT-314, a dual-targeting CD19/CD20 chimeric antigen receptor (CAR) T-cell product candidate, is being developed for patients with aggressive B-cell non-Hodgkin’s lymphoma.
The presentation, titled "First Results of IMPT-314, an Autologous Bispecific CD19/CD20 Chimeric Antigen Receptor (CAR) in Enriched Naive and Central Memory T Cells, for the Treatment of Large B Cell Lymphoma (LBCL)," will be given by Sarah M. Larson, M.D., Associate Professor at the David Geffen School of Medicine at UCLA.
IMPT-314: A Novel Approach to B-Cell Lymphoma
IMPT-314 is designed to target both CD19 and CD20 proteins found on B-cells, potentially offering a more robust approach to treating B-cell lymphomas compared to single-target CAR-T therapies. This dual-targeting strategy aims to reduce the risk of antigen escape, a common mechanism of resistance in CAR-T therapy.
The U.S. Food and Drug Administration has granted Fast Track Designation to IMPT-314 for the treatment of relapsed/refractory aggressive B-cell lymphoma, underscoring the unmet need and potential of this therapy.
The details of the presentation are as follows:
- Session Name: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III
- Publication Number: 4824
- Presentation Date & Time: Monday, December 9, 2024, 6:00 PM - 8:00 PM
- Location: San Diego Convention Center, Halls G-H
Lyell Immunopharma is focused on developing next-generation CAR T-cell therapies for both solid tumors and hematologic malignancies. Their technology is designed to enhance T cells, making them more resistant to exhaustion and promoting durable tumor cytotoxicity.
